CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 71 enrolled
Drug / intervention
tocilizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01705730
NCT01705730N/ACompleted
CompareCT.gov

Mon-ACT: A Multi-center, Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab in Monotherapy

Hoffmann-La Roche·observational·Posted Oct 12, 2012·Updated Sep 4, 2018

In Brief

An observational study evaluating tocilizumab for Rheumatoid Arthritis. Completed, enrolled 71 participants across 17 sites.

Detailed Summary

This observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in monotherapy in routine clinical practice in participants with rheumatoid arthritis. Eligible participants initiated on RoActemra/Actemra treatment according to the licensed label will be followed for 6 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 12, 2012
Enrollment StartJul 31, 2012
Primary CompletionDec 12, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 13.7 years ago

Interventions

tocilizumabdrug

Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.